Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 6
R&D Momentum
66/100
Pipeline Velocity
39/100
Trial Completion Rate
93/100
Pipeline Concentration
16/100
Pipeline Freshness
67/100
Strategic Signals
Activity
Last 14 days
Quantifying Hypothalamic GLP-1 Response in Healthy Weight and Obesity: A Randomized Crossover Neuroimaging Infusion Study
Development of a Risk Prediction Model for Graves' Orbitopathy Using Systematic Ophthalmological Data and Inflammatory Metabolic Biomarkers in Patients With Newly Diagnosed Graves' Disease
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)